China Tumor Genetic Testing IVD Devices: NMPA Registration, NGS Approvals & LDT Pilot (2025)
China's in vitro diagnostics (IVD) sector has emerged as one of the most dynamic segments within the country's ¥1.35 trillion medical device market. Nowhere is this dynamism more visible than in tumor genetic testing — a field where NGS multi-gene panels, PCR companion diagnostics, and methylation-based early detection tests are reaching Chinese patients at a pace that outstrips most other markets. Yet the regulatory pathway is demanding: over 150 IVD-specific guidance documents, mandatory clinical performance data for Class III products, and a fast-evolving landscape for laboratory-developed tests (LDTs). This article provides a practical overview for manufacturers and developers seeking NMPA registration for tumor genetic testing IVDs.
Why IVD Regulation Is Different in China
China's NMPA treats IVDs as a distinct category within medical devices — and for good reason. Unlike physical devices, IVDs derive their value entirely from the clinical information they generate. A sequencing instrument that produces inaccurate somatic mutation calls can lead to ineffective or harmful treatment decisions in ways that are invisible until outcomes data accumulates.
Accordingly, the regulatory framework emphasizes three things that differ in emphasis from hardware device review: (1) analytical performance — calibration traceability, accuracy, sensitivity, specificity, measurement range, and sample stability; (2) clinical performance — diagnostic sensitivity, specificity, PPV/NPV, likelihood ratios, and reference interval validation in the target population; and (3) the clinical intended use, stated precisely, because the same assay used for screening versus treatment monitoring carries different evidence requirements.
China's IVD regulatory authority has published more than 150 guidance documents covering both general principles (quantitative and qualitative performance evaluation) and product-specific technical review guidelines. For tumor gene diagnostics, product-specific guidance exists for MSI detection, Septin9 methylation, SDC2 methylation, HER2 FISH, EGFR PCR, BRCA NGS, TMB measurement, and breast cancer molecular subtyping — among others.
Classification: Almost Every Tumor Gene Test Is Class III
China's IVD classification system follows a risk-based framework aligned with IMDRF principles. In practice, virtually every tumor genetic testing product falls into Class III (highest risk), which requires NMPA pre-market registration. This includes:
- NGS multi-gene panels for somatic mutation detection (lung, colorectal, breast, hematologic malignancies)
- PCR-based companion diagnostics (EGFR, KRAS, BRAF, ALK, ROS1, HER2, and combination panels)
- DNA methylation detection kits for cancer screening or diagnosis (SDC2, Septin9, RNF180, KRAS methylation, CDO1/AJAP1/GALR1, etc.)
- MSI detection reagents (fluorescent capillary electrophoresis or NGS-based)
- TMB assessment kits
- PD-L1 protein detection reagents with companion diagnostic claims
- Sequencing instruments used clinically (also Class III, reviewed independently from their reagent kits)
Calibration materials (校准品) and quality controls (质控品) accompanying Class III IVD products are included within the registration scope and must meet separate analytical performance requirements including traceability and assigned-value validation.
Market Snapshot: What Has Actually Been Approved
As of 2025, the NMPA-approved landscape for tumor genetic testing IVDs reflects both the market's growth and the regulatory system's caution with novel technologies.
NGS Sequencing Instruments
China was the first major market outside the US to build a domestic NGS sequencer ecosystem. Since the first sequencing instrument was approved in 2014, more than 30 products from over 20 companies have received NMPA registration. Approved sequencing technologies include: reversible terminator sequencing (Illumina-equivalent), semiconductor sequencing (Ion Torrent-equivalent), combinatorial probe-anchor ligation (CPLAP, used by BGI's DNBSEQ), DNA nanoball sequencing, and single-molecule fluorescence sequencing.
Sequencing instruments and their paired library preparation reagents are reviewed independently under separate registrations — a distinction that often surprises foreign companies accustomed to a single FDA PMA submission covering the instrument-reagent system.
NGS Reagent Kits: A Concentrated Market
Of the 29 NGS tumor reagent kits approved through 2024, the gene coverage is strikingly concentrated: EGFR, KRAS, BRAF, and ALK together appear in the majority of products, and all 29 products collectively cover only 12 key genes. Cancer type coverage is similarly focused: non-small cell lung cancer, colorectal cancer, and ovarian cancer dominate, reflecting the therapeutic landscape where EGFR-TKIs, ALK-TKIs, and PARP inhibitors first received Chinese approval.
PCR Companion Diagnostics: 85 Products, Two Dominant Genes
PCR-based tumor gene kits show even greater concentration: of the 85 approved products, EGFR and KRAS each appear in 22 products — intense market competition for the most commercially important targets. Tissue sampling dominates, with liquid biopsy (blood/plasma) coverage limited primarily to NSCLC (EGFR) and BCR-ABL for CML. The gap between tissue-based and liquid biopsy approvals reflects the higher clinical evidence burden for circulating tumor DNA assays.
DNA Methylation: 37 Kits, Colorectal Cancer Leading
DNA methylation-based tests have grown rapidly. As of March 2025, 37 methylation detection kits hold NMPA registration, covering 8 cancer types. Colorectal cancer dominates with 16 products — driven largely by the clinical success of SDC2 and Septin9 methylation as stool- or blood-based colorectal cancer screening markers. Lung cancer (3 products), cervical cancer (3 products), bladder/urothelial cancer (3 products), esophageal cancer (2 products), gastric cancer (2 products), endometrial cancer (1 product), and hepatic cancer (1 product) round out the landscape.
NMPA's technical review approach for methylation products is notably rigorous: regulators require systematic evaluation of all clinical research supporting the chosen methylation marker, including adequacy of study design, sample size, and the statistical validity of the published conclusions. For ctDNA-based methylation assays targeting early-stage disease, sensitivity/specificity challenges in low-tumor-burden samples remain an active scientific and regulatory issue.
Clinical Evaluation Pathways: Three Routes to NMPA Approval
China's IVD clinical evaluation framework offers three distinct pathways, and selecting the right one is critical to both timeline and cost:
Pathway 1: Exemption (Class I only)
Class I IVDs — calibration materials, quality controls, and general laboratory reagents — are exempt from clinical evaluation. No tumor genetic testing product currently on the market falls into this category.
Pathway 2: Predicate Comparator (Comparator Study, 同品种比对)
Most Class II IVDs, and some Class III products, can demonstrate clinical performance by comparing to an already-registered predicate device using the same analytical principle. This pathway avoids a clinical trial but requires rigorous analytical performance bridging data and a scientifically defensible demonstration that the subject product performs equivalently to the predicate across the clinical indications claimed.
For tumor genetic testing IVDs, the comparator pathway is available to new PCR kits targeting already-approved genes where a registered predicate exists, and to some NGS applications where a comparable registered product can be identified. However, NMPA has tightened scrutiny on comparator claims for genuinely novel platforms or new gene/cancer combinations.
Pathway 3: Clinical Trial (高风险三类产品 & 新产品)
High-risk Class III IVDs and products with no established predicate must complete a clinical trial in China. Requirements include: prospective or retrospective collection of clinical specimens from Chinese patients, performance evaluation against a reference method (histopathology, orthogonal molecular testing), clinical diagnostic sensitivity and specificity for the stated indication, and — for companion diagnostics — concordance with the therapeutic decision being supported.
For novel NGS platforms, first-in-class methylation markers, and new liquid biopsy applications, the clinical trial pathway is typically unavoidable. NMPA encourages early engagement (pre-submission meetings) for complex products.
Companion Diagnostics: Original vs. Non-Original CDx
China has developed one of the world's most detailed regulatory frameworks specifically for companion diagnostics — distinguishing between two CDx types that have very different regulatory paths:
Original CDx Co-developed with the Drug (原研伴随诊断)
When a CDx is developed in parallel with an anticancer drug and is essential to the drug's approved labeling, it follows the co-development pathway. NMPA reviews the CDx in coordination with the drug review, and the clinical evidence from the drug's pivotal trial is expected to form part of the CDx's clinical validation package. The guidance document (《与抗肿瘤药物同步研发的原研伴随诊断试剂临床试验注册审查指导原则》) sets out specific requirements for the clinical trial design, concordance analysis, and labeling claims.
Non-Original CDx for Already-Approved Drugs (非原研伴随诊断)
When a company seeks NMPA approval for a CDx that supports an already-approved drug — for example, a new EGFR kit to select patients for an approved TKI — it must demonstrate clinical equivalence to the original CDx or to the reference method used in the drug trial. The guidance document (《抗肿瘤药物的非原研伴随诊断试剂临床试验注册审查指导原则》) is specific about the bridging study design, analytical comparisons, and what constitutes acceptable concordance.
PD-L1 Detection Reagents
PD-L1 IHC kits have their own separate guidance (《PD-L1检测试剂临床试验—结果重现性研究注册审查指导原则》) focused specifically on inter-laboratory and inter-reader reproducibility — a critical issue because PD-L1 scoring varies substantially between antibody clones, scoring algorithms, and readers.
LDT Pilot: The Emerging In-House Testing Pathway
One of the most significant recent developments in Chinese IVD regulation is the formalization of laboratory-developed tests (LDTs) as a regulated category. Article 53 of the 2021 Medical Device Regulations (条例第五十三条) for the first time provided explicit legal authorization for qualified medical institutions to self-develop and use IVDs for in-house clinical purposes, under physician supervision — without a separate NMPA registration.
A national LDT pilot program has since been established, with Shanghai running a formal pilot scheme and Beijing announcing in its 2025 innovation support measures that it will prioritize rare disease diagnostics for LDT designation. The Beijing 2025 document (《北京市支持创新医药高质量发展若干措施》) specifically calls for accelerating the LDT pilot for medical institutions and completing the designated number of pilot product filings.
Key LDT requirement: LDT products under the pilot program are restricted to in-house clinical use at the developing institution, under direct physician supervision, and cannot be commercially distributed. Institutions participating in pilots must meet specified quality, personnel, and adverse event monitoring standards. The LDT framework is not a substitute for NMPA registration for commercially distributed products.
For tumor genetic testing specifically, LDT status is of particular interest for highly specialized genomic tests — whole exome sequencing, comprehensive genomic profiling (CGP) panels, pharmacogenomic panels — where the evidence base may not yet support a full Class III registration but where unmet clinical need is clear.
Technical Standards for Tumor Gene IVDs
In addition to guidance documents, tumor gene testing IVDs must comply with relevant mandatory standards. Key standards in force include:
- YY/T 1261-2015 — HER2 gene detection kits (FISH method)
- YY/T 1586-2018 — Tumor individualized treatment gene mutation detection kits (fluorescence PCR)
- YY/T 1591-2017 — Human EGFR gene mutation detection kits
- YY/T 1865-2022 — BRCA gene mutation detection kits and database general technical requirements (NGS method)
- YY/T 1892-2024 — BCR-ABL fusion gene detection kits
- YY/T 1224-2014 — Bladder cancer chromosomal and gene abnormality detection kits (FISH)
Software integrated into NGS analysis platforms (variant calling, report generation) is regulated as Software as a Medical Device (SaMD). NMPA requires that software for human gene mutation PCR analyzers meet at minimum a "medium level" cybersecurity and software lifecycle documentation standard.
Innovative IVD Track: 24 Approvals in 10 Years
Between 2014 and 2024, NMPA granted Innovative Medical Device designation to 315 products, of which only 24 (8%) were IVDs — reflecting the sector's complexity relative to hardware devices. Notable IVD firsts on the innovation track include: China's first NGS sequencer (华因康, 2014), the first BCR-ABL liquid biopsy PCR kit (2015), first NGS multi-gene lung cancer CDx (广州燃石, 2018), first NGS colorectal cancer CDx (南京世和, 2018), first preimplantation chromosome aneuploidy NGS kit (2021), first NGS-based TMB kit (南京世和, 2023), and the first KRAS/BMP3/NDRG4/fecal occult blood combined colorectal cancer screening kit (杭州诺辉, 2020 — the commercial product behind 常卫清).
The Innovative Medical Device pathway provides priority review, closer regulator-manufacturer dialogue, and early market entry — but requires genuine clinical novelty and a clear unmet clinical need. It is not a shortcut for products with established predicates.
Common Submission Challenges
- Calibration traceability gaps: For quantitative assays, traceability of calibrators to reference materials (国家标准品, WHO international standards) must be fully documented. Gaps here trigger major deficiency letters.
- Insufficient reference method comparisons: Clinical performance claims require comparison against an accepted reference standard (e.g., Sanger sequencing, IHC, orthogonal NGS). Studies using only the test's own repeated measurements do not satisfy this requirement.
- Liquid biopsy sensitivity claims without adequate LOD validation: ctDNA-based tests making early-detection or MRD (minimal residual disease) claims require rigorous limit of detection (LOD) characterization with clinically relevant variant allele frequency (VAF) levels.
- Inadequate interference studies: Sample matrix variables (hemolysis, lipemia, bilirubin, common medications, germline variants) must be systematically evaluated for all cancer types in scope.
- Bioinformatics pipeline underdocumentation: For NGS products, the variant calling pipeline, filtering algorithms, and version-controlled software documentation must be submitted. Retrospective pipeline changes without re-validation are a common audit finding.
FAQ
Most tumor genetic testing IVDs — NGS panels, PCR companion diagnostics, methylation kits, and MSI/TMB tests — are Class III (highest risk) under China's classification system. Class III IVDs require full NMPA pre-market registration with clinical performance data. Sequencing instruments used clinically are also Class III, registered independently from their reagent kits.
High-risk Class III products with no established predicate must complete clinical trials in China. Some NGS products have used the comparator pathway (同品种比对) against an already-approved predicate, but NMPA has tightened scrutiny for genuinely novel platforms or new gene/cancer combinations. For first-in-class NGS applications and new liquid biopsy technologies, a clinical trial is typically required.
China's LDT pilot was authorized by Article 53 of the 2021 Medical Device Regulations, allowing qualified medical institutions to self-develop IVDs for in-house clinical use without separate NMPA registration. National and Shanghai pilots are underway; Beijing's 2025 innovation measures call for accelerating the pilot with priority for rare disease diagnostics. LDT products cannot be commercially distributed and must be used under direct physician supervision.
China has separate guidance for original CDx co-developed with an anticancer drug (parallel NMPA review with the drug) and non-original CDx for already-approved drugs (must demonstrate clinical equivalence to the original CDx or the reference method). PD-L1 detection reagents have dedicated reproducibility guidance. CDx claims must be precisely stated in labeling and cannot extend beyond the approved intended use.
NMPA's official technical review clock for Class III IVDs is 60 working days, but total elapsed time including clinical trial conduct (12–24 months for a prospective study), dossier preparation, pre-submission consultations, and response rounds typically ranges from 3 to 5 years for a novel IVD with no established predicate. Products using the comparator pathway with a well-matched predicate may complete registration in 18–30 months if dossier quality is high.
Planning an NMPA Submission for a Tumor Genetic Testing IVD?
Our team includes former NMPA technical reviewers with direct experience assessing NGS, PCR, and methylation IVD dossiers. We can assess your product's classification, identify the optimal clinical evaluation pathway, and structure a submission strategy that avoids the most common deficiency triggers.
Book a Free Consultation →